Flt-3 Ligand Inhibits Growth of Human Ovarian Tumors Engrafted in Severe Combined Immunodeficient Mice
- 1 June 2000
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 77 (3) , 377-382
- https://doi.org/10.1006/gyno.2000.5782
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Characterization of Human Ovarian Carcinomas in a SCID Mouse ModelGynecologic Oncology, 1999
- Effects of IL-12 on Human Ovarian Tumors Engrafted into SCID MiceGynecologic Oncology, 1999
- Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I studyCancer, 1997
- Flt3 ligand induces tumor regression and antitumor immune responses in vivoNature Medicine, 1997
- Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II StudyGynecologic Oncology, 1997
- Molecular Mechanisms of Lymphocyte-Mediated Cytotoxicity and Their Role in Immunological Protection and Pathogenesis In VivoAnnual Review of Immunology, 1996
- Biology of Flt3 Ligand, a Novel Regulator of Hematopoietic Stem and Progenitor CellsPublished by Springer Nature ,1996
- International Journal of HematologyInternational Journal of Hematology, 1995
- Biologic Therapy in the Management of Refractory Ovarian CancerGynecologic Oncology, 1993
- A glycolipid on the surface of mouse natural killer cellsEuropean Journal of Immunology, 1980